Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 2000 Jan;53(1):55–59. doi: 10.1136/jcp.53.1.55

Therapeutic trials in childhood ALL: what's their future?

O Eden 1
PMCID: PMC1731071  PMID: 10767858

Full Text

The Full Text of this article is available as a PDF (96.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biondi A., Yokota S., Hansen-Hagge T. E., Rossi V., Giudici G., Maglia O., Basso G., Tell C., Masera G., Bartram C. R. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia. 1992 Apr;6(4):282–288. [PubMed] [Google Scholar]
  2. Borkhardt A., Cazzaniga G., Viehmann S., Valsecchi M. G., Ludwig W. D., Burci L., Mangioni S., Schrappe M., Riehm H., Lampert F. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood. 1997 Jul 15;90(2):571–577. [PubMed] [Google Scholar]
  3. Chessells J. M., Bailey C., Richards S. M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet. 1995 Jan 21;345(8943):143–148. doi: 10.1016/s0140-6736(95)90164-7. [DOI] [PubMed] [Google Scholar]
  4. Chessells J. M., Eden O. B., Bailey C. C., Lilleyman J. S., Richards S. M. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia. 1994 Aug;8(8):1275–1279. [PubMed] [Google Scholar]
  5. Chessells J. M., Hall E., Prentice H. G., Durrant J., Bailey C. C., Richards S. M. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998 Apr;12(4):463–473. doi: 10.1038/sj.leu.2400959. [DOI] [PubMed] [Google Scholar]
  6. Chessels J. M., Swansbury G. J., Reeves B., Bailey C. C., Richards S. M. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol. 1997 Oct;99(1):93–100. doi: 10.1046/j.1365-2141.1997.3493163.x. [DOI] [PubMed] [Google Scholar]
  7. D'Arcy Hart P. A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s. BMJ. 1999 Aug 28;319(7209):572–573. doi: 10.1136/bmj.319.7209.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davies H. A., Lennard L., Lilleyman J. S. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ. 1993 May 8;306(6887):1239–1240. doi: 10.1136/bmj.306.6887.1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Eden O. B., Lilleyman J. S., Richards S., Shaw M. P., Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol. 1991 Jun;78(2):187–196. doi: 10.1111/j.1365-2141.1991.tb04415.x. [DOI] [PubMed] [Google Scholar]
  10. Evans W. E., Relling M. V. Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res. 1994 Nov;18(11):811–814. doi: 10.1016/0145-2126(94)90160-0. [DOI] [PubMed] [Google Scholar]
  11. Evans W. E., Relling M. V., Rodman J. H., Crom W. R., Boyett J. M., Pui C. H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998 Feb 19;338(8):499–505. doi: 10.1056/NEJM199802193380803. [DOI] [PubMed] [Google Scholar]
  12. Gaynon P. S., Steinherz P. G., Bleyer W. A., Ablin A. R., Albo V. C., Finklestein J. Z., Grossman N. J., Novak L. J., Pyesmany A. F., Reaman G. H. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol. 1993 Nov;11(11):2234–2242. doi: 10.1200/JCO.1993.11.11.2234. [DOI] [PubMed] [Google Scholar]
  13. Goodman N. W. Who will challenge evidence-based medicine? J R Coll Physicians Lond. 1999 May-Jun;33(3):249–251. [PMC free article] [PubMed] [Google Scholar]
  14. Hann I. M., Eden O. B., Barnes J., Pinkerton C. R. 'MACHO' chemotherapy for stage IV B cell lymphoma and B cell acute lymphoblastic leukaemia of childhood. United Kingdom Children's Cancer Study Group (UKCCSG). Br J Haematol. 1990 Nov;76(3):359–364. doi: 10.1111/j.1365-2141.1990.tb06368.x. [DOI] [PubMed] [Google Scholar]
  15. Hann I. M., Richards S. M., Eden O. B., Hill F. G. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia. 1998 Aug;12(8):1249–1255. doi: 10.1038/sj.leu.2401093. [DOI] [PubMed] [Google Scholar]
  16. Hill A. B. Suspended judgment. Memories of the British Streptomycin Trial in Tuberculosis. The first randomized clinical trial. Control Clin Trials. 1990 Apr;11(2):77–79. doi: 10.1016/0197-2456(90)90001-i. [DOI] [PubMed] [Google Scholar]
  17. Kaspers G. J., Smets L. A., Pieters R., Van Zantwijk C. H., Van Wering E. R., Veerman A. J. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood. 1995 Feb 1;85(3):751–756. [PubMed] [Google Scholar]
  18. Kaspers G. J., Veerman A. J., Pieters R., Van Zantwijk C. H., Smets L. A., Van Wering E. R., Van Der Does-Van Den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997 Oct 1;90(7):2723–2729. [PubMed] [Google Scholar]
  19. Lennard L., Davies H. A., Lilleyman J. S. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer. 1993 Jul;68(1):186–190. doi: 10.1038/bjc.1993.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  21. Lilleyman J. S., Gibson B. E., Stevens R. F., Will A. M., Hann I. M., Richards S. M., Hill F. G. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol. 1997 Jun;97(3):603–606. doi: 10.1046/j.1365-2141.1997.1002914.x. [DOI] [PubMed] [Google Scholar]
  22. Meadows A. T., Kramer S., Hopson R., Lustbader E., Jarrett P., Evans A. E. Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment. Cancer Invest. 1983;1(1):49–55. doi: 10.3109/07357908309040932. [DOI] [PubMed] [Google Scholar]
  23. Nachman J. B., Sather H. N., Sensel M. G., Trigg M. E., Cherlow J. M., Lukens J. N., Wolff L., Uckun F. M., Gaynon P. S. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998 Jun 4;338(23):1663–1671. doi: 10.1056/NEJM199806043382304. [DOI] [PubMed] [Google Scholar]
  24. Parmar M. K., Stewart L. A., Altman D. G. Meta-analyses of randomised trials: when the whole is more than just the sum of the parts. Br J Cancer. 1996 Aug;74(4):496–501. doi: 10.1038/bjc.1996.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Patte C. Non-Hodgkin's lymphoma. Eur J Cancer. 1998 Feb;34(3):359–363. doi: 10.1016/s0959-8049(97)10142-3. [DOI] [PubMed] [Google Scholar]
  26. Patte C., Philip T., Rodary C., Zucker J. M., Behrendt H., Gentet J. C., Lamagnère J. P., Otten J., Dufillot D., Pein F. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991 Jan;9(1):123–132. doi: 10.1200/JCO.1991.9.1.123. [DOI] [PubMed] [Google Scholar]
  27. Peto R. Why do we need systematic overviews of randomized trials? Stat Med. 1987 Apr-May;6(3):233–244. doi: 10.1002/sim.4780060306. [DOI] [PubMed] [Google Scholar]
  28. Pieters R., Huismans D. R., Loonen A. H., Hählen K., van der Does-van den Berg A., van Wering E. R., Veerman A. J. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991 Aug 17;338(8764):399–403. doi: 10.1016/0140-6736(91)91029-t. [DOI] [PubMed] [Google Scholar]
  29. Pieters R., den Boer M. L., Durian M., Janka G., Schmiegelow K., Kaspers G. J., van Wering E. R., Veerman A. J. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia. 1998 Sep;12(9):1344–1348. doi: 10.1038/sj.leu.2401129. [DOI] [PubMed] [Google Scholar]
  30. Pui C. H., Carroll A. J., Raimondi S. C., Land V. J., Crist W. M., Shuster J. J., Williams D. L., Pullen D. J., Borowitz M. J., Behm F. G. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood. 1990 Mar 1;75(5):1170–1177. [PubMed] [Google Scholar]
  31. Pui C. H., Evans W. E. Acute lymphoblastic leukemia. N Engl J Med. 1998 Aug 27;339(9):605–615. doi: 10.1056/NEJM199808273390907. [DOI] [PubMed] [Google Scholar]
  32. Pui C. H., Kane J. R., Crist W. M. Biology and treatment of infant leukemias. Leukemia. 1995 May;9(5):762–769. [PubMed] [Google Scholar]
  33. Pui C. H., Raimondi S. C., Head D. R., Schell M. J., Rivera G. K., Mirro J., Jr, Crist W. M., Behm F. G. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood. 1991 Sep 1;78(5):1327–1337. [PubMed] [Google Scholar]
  34. Reiter A., Schrappe M., Ludwig W. D., Hiddemann W., Sauter S., Henze G., Zimmermann M., Lampert F., Havers W., Niethammer D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994 Nov 1;84(9):3122–3133. [PubMed] [Google Scholar]
  35. Ribeiro R. C., Broniscer A., Rivera G. K., Hancock M. L., Raimondi S. C., Sandlund J. T., Crist W., Evans W. E., Pui C. H. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia. 1997 Sep;11(9):1493–1496. doi: 10.1038/sj.leu.2400749. [DOI] [PubMed] [Google Scholar]
  36. Richards S., Burrett J., Hann I., Chessells J., Hill F., Bailey C. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia. Leukemia. 1998 Jul;12(7):1031–1036. doi: 10.1038/sj.leu.2401065. [DOI] [PubMed] [Google Scholar]
  37. Satti M. B., Weinbren K., Gordon-Smith E. C. 6-thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol. 1982 Oct;35(10):1086–1091. doi: 10.1136/jcp.35.10.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Smith M., Arthur D., Camitta B., Carroll A. J., Crist W., Gaynon P., Gelber R., Heerema N., Korn E. L., Link M. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan;14(1):18–24. doi: 10.1200/JCO.1996.14.1.18. [DOI] [PubMed] [Google Scholar]
  39. Sniderman A. D. Clinical trials, consensus conferences, and clinical practice. Lancet. 1999 Jul 24;354(9175):327–330. doi: 10.1016/S0140-6736(98)11185-6. [DOI] [PubMed] [Google Scholar]
  40. Steinherz P. G., Gaynon P. S., Breneman J. C., Cherlow J. M., Grossman N. J., Kersey J. H., Johnstone H. S., Sather H. N., Trigg M. E., Chappell R. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol. 1996 Feb;14(2):389–398. doi: 10.1200/JCO.1996.14.2.389. [DOI] [PubMed] [Google Scholar]
  41. Stiller C. A., Draper G. J. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child. 1989 May;64(5):657–661. doi: 10.1136/adc.64.5.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stiller C. A., Eatock E. M. Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Arch Dis Child. 1999 Sep;81(3):202–208. doi: 10.1136/adc.81.3.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Veerman A. J., Hählen K., Kamps W. A., Van Leeuwen E. F., De Vaan G. A., Solbu G., Suciu S., Van Wering E. R., Van der Does-Van der Berg A. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996 Mar;14(3):911–918. doi: 10.1200/JCO.1996.14.3.911. [DOI] [PubMed] [Google Scholar]
  44. Wheeler K., Chessells J. M., Bailey C. C., Richards S. M. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child. 1996 Feb;74(2):101–107. doi: 10.1136/adc.74.2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Whitehead V. M., Vuchich M. J., Lauer S. J., Mahoney D., Carroll A. J., Shuster J. J., Esseltine D. W., Payment C., Look A. T., Akabutu J. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1992 Sep 1;80(5):1316–1323. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES